What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Pharmaceutical

PUBLISHER: IMARC | PRODUCT CODE: 1519762

PUBLISHER: IMARC | PRODUCT CODE: 1519762

Antihyperlipidemic Drugs Market Report by Drug Class, Route of Administration, Distribution Channel, and Region 2024-2032

PUBLISHED: July 1, 2024

PAGES: 136 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

The global antihyperlipidemic drugs market size reached US$ 12.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 18.2 Billion by 2032, exhibiting a growth rate (CAGR) of 4.1% during 2024-2032.

Antihyperlipidemic drugs help lower serum levels of cholesterol and various lipids in the blood. They can be taken with different medications to control high cholesterol and reduce the risk of certain medical conditions. At present, their different classes are available worldwide, which can be given based on the patient's cholesterol profile, underlying disease, and other factors. Some of the commonly available antihyperlipidemic drugs include statins, antihyperlipidemic combinations, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and PCSK9 inhibitors.

Antihyperlipidemic Drugs Market Trends:

The growing prevalence of hyperlipidemia on account of sedentary lifestyles, nicotine addiction, and high consumption of fatty foods represents one of the key factors catalyzing the demand for antihyperlipidemic drugs. Moreover, hyperlipidemia increases the risk of developing coronary artery disease (CAD), which is the most common cause of death among adults worldwide. As a result, there is a rise in the need for these drugs to reduce the high levels of low-density lipoprotein (LDL) cholesterol and triglycerides while increasing the low levels of high-density lipoprotein (HDL) cholesterol. Apart from this, they are used to treat children with high cholesterol levels and various lipid disorders. In addition, a surge in the number of genetic and acquired disorders of lipid and lipoprotein metabolism among the pediatric population is positively influencing the need for antihyperlipidemic drugs to reduce the rates of hospitalization and premature deaths. Furthermore, the approval of new and advanced drugs is creating a favorable outlook for the market. Besides this, medicinal chemists around the world are designing, synthesizing, and evaluating a variety of new molecules for these drugs, which is anticipated to contribute to the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antihyperlipidemic drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class, route of administration and distribution channel.

Breakup by Drug Class:

Statins

Bile Acid Sequestrants

Cholesterol Absorption Inhibitors

Fibric Acid Derivatives

PCSK9 Inhibitors

Combination

Others

Breakup by Route of Administration:

Oral

Intravenous

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Stores

Online Retailers

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Sanofi S.A.

Key Questions Answered in This Report

1. What was the size of the global antihyperlipidemic drugs market in 2023?
2. What is the expected growth rate of the global antihyperlipidemic drugs market during 2024-2032?
3. What are the key factors driving the global antihyperlipidemic drugs market?
4. What has been the impact of COVID-19 on the global antihyperlipidemic drugs market?
5. What is the breakup of the global antihyperlipidemic drugs market based on the drug class?
6. What is the breakup of the global antihyperlipidemic drugs market based on the distribution channel?
7. What are the key regions in the global antihyperlipidemic drugs market?
8. Who are the key players/companies in the global antihyperlipidemic drugs market?

Product Code: SR112024A5622

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Antihyperlipidemic Drugs Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Drug Class

6.1 Statins
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Bile Acid Sequestrants
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Cholesterol Absorption Inhibitors
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Fibric Acid Derivatives
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 PCSK9 Inhibitors
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
6.6 Combination
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
6.7 Others
- 6.7.1 Market Trends
- 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

7.1 Oral
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Intravenous
- 7.2.1 Market Trends
- 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

8.1 Hospital Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Retail Stores
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Online Retailers
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Amgen Inc.
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
  - 14.3.1.3 Financials
- 14.3.2 AstraZeneca plc
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
  - 14.3.2.3 Financials
  - 14.3.2.4 SWOT Analysis
- 14.3.3 Daiichi Sankyo Company Limited
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 Financials
  - 14.3.3.4 SWOT Analysis
- 14.3.4 Merck & Co. Inc.
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
  - 14.3.4.3 Financials
- 14.3.5 Novartis AG
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
  - 14.3.5.3 Financials
  - 14.3.5.4 SWOT Analysis
- 14.3.6 Pfizer Inc.
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
  - 14.3.6.3 Financials
- 14.3.7 Sanofi S.A
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 Financials

Product Code: SR112024A5622

List of Figures

Figure 1: Global: Antihyperlipidemic Drugs Market: Major Drivers and Challenges
Figure 2: Global: Antihyperlipidemic Drugs Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Antihyperlipidemic Drugs Market: Breakup by Drug Class (in %), 2023
Figure 5: Global: Antihyperlipidemic Drugs Market: Breakup by Route of Administration (in %), 2023
Figure 6: Global: Antihyperlipidemic Drugs Market: Breakup by Distribution Channel (in %), 2023
Figure 7: Global: Antihyperlipidemic Drugs Market: Breakup by Region (in %), 2023
Figure 8: Global: Antihyperlipidemic Drugs (Statins) Market: Sales Value (in Million US$), 2018 & 2023
Figure 9: Global: Antihyperlipidemic Drugs (Statins) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 10: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Antihyperlipidemic Drugs (Combination) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Antihyperlipidemic Drugs (Combination) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Antihyperlipidemic Drugs (Oral) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Antihyperlipidemic Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Global: Antihyperlipidemic Drugs (Intravenous) Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Global: Antihyperlipidemic Drugs (Intravenous) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Global: Antihyperlipidemic Drugs (Retail Stores) Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Global: Antihyperlipidemic Drugs (Retail Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Global: Antihyperlipidemic Drugs (Online Retailers) Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Global: Antihyperlipidemic Drugs (Online Retailers) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: North America: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: North America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: United States: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: United States: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: Canada: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: Canada: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: Asia-Pacific: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: Asia-Pacific: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: China: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: China: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: Japan: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: Japan: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: India: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: India: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: South Korea: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: South Korea: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: Australia: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: Australia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: Indonesia: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: Indonesia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: Europe: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: Europe: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: Germany: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: Germany: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: France: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: France: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: United Kingdom: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: United Kingdom: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: Italy: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: Italy: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Spain: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Spain: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Russia: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Russia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Latin America: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Latin America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: Brazil: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 73: Brazil: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 74: Mexico: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 75: Mexico: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 76: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 77: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 78: Middle East and Africa: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 79: Middle East and Africa: Antihyperlipidemic Drugs Market: Breakup by Country (in %), 2023
Figure 80: Middle East and Africa: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 81: Global: Antihyperlipidemic Drugs Industry: SWOT Analysis
Figure 82: Global: Antihyperlipidemic Drugs Industry: Value Chain Analysis
Figure 83: Global: Antihyperlipidemic Drugs Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Antihyperlipidemic Drugs Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
Table 3: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
Table 4: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
Table 5: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Antihyperlipidemic Drugs Market: Competitive Structure
Table 7: Global: Antihyperlipidemic Drugs Market: Key Players